Telitacicept for PGNMID: A Single-Arm Study
NCT07111338
·
clinicaltrials.gov ↗
PHASE2
Phase
ACTIVE_NOT_RECRUITING
Status
10
Enrollment
OTHER
Sponsor class
Conditions
Proliferative Glomerulonephritis With Monoclonal Immunoglobulin Deposits
Interventions
DRUG:
Telitacicept 160mg
Sponsor
Peking University First Hospital